-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Pharmaceutical Stock Market] In the past two weeks, the CSI 300 Index and the Pharmaceutical Bio (Shenwan) Index have fallen one after another, down 88% and 87% respective.
However, from the perspective of individual stocks, there are still many pharmaceutical stocks rising against the trend, among which , the three pharmaceutical stocks of Kangzhong Medical, Nanxin Pharmaceutical, and *ST Hengkang all rose by more than 3
On the news, the Beijing Municipal Medical Insurance Bureau recently issued a notice that new drugs and new technologies will be excluded from CHS-DRG payment manageme.
Orient Securities believes that Beijing's promotion of DRG innovative drugs and devices except payment will benefit real innovative drugs and devic.
Kangzhong Medical: Up 363% Specifically, Kangzhong Medical has risen by 363% in the past two wee.
As of the close on July 18, the stock closed at 37 yuan, up 99%, with a turnover rate of 05% and a trading volume of 99 10,000 lots, with a turnover of 73284 million yu.
In terms of capital flow data, on July 18, the net inflow of main funds was 7332 million yuan, the net outflow of hot funds was 1734 million yuan, and the net outflow of retail funds was 5598 million yu.
According to the data, Kangzhong Medical is an enterprise specializing in the research and development, production, sales and service of digital X-ray flat panel detecto.
Since its establishment, the company has always been committed to the digital X-ray flat panel detector indust.
With its strong R&D strength and production capacity, it has mastered key technologies such as the design and manufacture of amorphous silicon TFT/PD, and the evaporation and packaging of cesium iodi.
At present, the products have gradually extended from medical general radiology to breast, dynamic fluoroscopy, radiotherapy, oral 3D imaging and other fields, and further expanded to the fields of industry, security inspection, and pet medical ca.
The 2021 annual report shows that the company achieved operating income of 342 million yuan, a year-on-year increase of 81%, net profit of 809 million yuan, a year-on-year increase of 124%, and basic earnings per share of 99 yu.
Nanxin Pharmaceutical: up 356% Nanxin Pharmaceutical followed closely with an increase of 356% in the past two wee.
As of the close on July 18, Nanxin Pharmaceutical closed at 322 yuan, up 38%, with a turnover rate of 81%, a trading volume of 38,200 lots, and a turnover of 121 million yu.
In terms of capital flow data, on July 18, the net inflow of main funds was 13811 million yuan, the net outflow of hot funds was 4961 million yuan, and the net outflow of retail funds was 1885 million yu.
According to the data, Nanxin Pharmaceutical is a high-tech pharmaceutical company specializing in the research and development, production and sales of antiviral and infectious disease prevention and treatment drugs such as influenza, as well as drugs for the treatment of malignant tumors, diabetes and other major diseas.
The 2021 annual performance report shows that the company achieved an operating income of 685 million yuan, a year-on-year decrease of 308%; realized a net profit attributable to shareholders of the listed company of -167 million yuan, a year-on-year stop profit and turned a loss; the basic earnings per share lost 19 yu.
*ST Hengkang: up 303% In addition, *ST Hengkang also rose by more than 30%, reaching 30
As of the close on July 18, 2022, the stock closed at 35 yuan, up 46%, with a turnover rate of 15%, a trading volume of 372,900 lots, and a turnover of 161 million yu.
In terms of capital flow data, on July 18, the net outflow of main funds was 24237 million yuan, the net outflow of hot funds was 1683 million yuan, and the net inflow of retail funds was 2592 million yu.
*ST Hengkang is mainly engaged in medical services and pharmaceutical manufacturi.
The company is based on the "two-wheel drive" big health industry of these two major business.
With medical services as the core, it builds a comprehensive strategic layout for colleges and universities, and its business covers diagnosis, treatment, nursing, Rehabilitation, medical care and other whole industry chains, and at the same time give full play to the discipline advantages of each hospital, build a regional medical center, and form a differentiated competitiveness
In 2021, the company will achieve an operating income of about 016 billion yuan, a year-on-year increase of 49%; the net profit loss attributable to shareholders of the listed company is about 371 million yuan; the basic earnings per share loss is 1991 yu.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
However, from the perspective of individual stocks, there are still many pharmaceutical stocks rising against the trend, among which , the three pharmaceutical stocks of Kangzhong Medical, Nanxin Pharmaceutical, and *ST Hengkang all rose by more than 3
On the news, the Beijing Municipal Medical Insurance Bureau recently issued a notice that new drugs and new technologies will be excluded from CHS-DRG payment manageme.
Orient Securities believes that Beijing's promotion of DRG innovative drugs and devices except payment will benefit real innovative drugs and devic.
Kangzhong Medical: Up 363% Specifically, Kangzhong Medical has risen by 363% in the past two wee.
As of the close on July 18, the stock closed at 37 yuan, up 99%, with a turnover rate of 05% and a trading volume of 99 10,000 lots, with a turnover of 73284 million yu.
In terms of capital flow data, on July 18, the net inflow of main funds was 7332 million yuan, the net outflow of hot funds was 1734 million yuan, and the net outflow of retail funds was 5598 million yu.
According to the data, Kangzhong Medical is an enterprise specializing in the research and development, production, sales and service of digital X-ray flat panel detecto.
Since its establishment, the company has always been committed to the digital X-ray flat panel detector indust.
With its strong R&D strength and production capacity, it has mastered key technologies such as the design and manufacture of amorphous silicon TFT/PD, and the evaporation and packaging of cesium iodi.
At present, the products have gradually extended from medical general radiology to breast, dynamic fluoroscopy, radiotherapy, oral 3D imaging and other fields, and further expanded to the fields of industry, security inspection, and pet medical ca.
The 2021 annual report shows that the company achieved operating income of 342 million yuan, a year-on-year increase of 81%, net profit of 809 million yuan, a year-on-year increase of 124%, and basic earnings per share of 99 yu.
Nanxin Pharmaceutical: up 356% Nanxin Pharmaceutical followed closely with an increase of 356% in the past two wee.
As of the close on July 18, Nanxin Pharmaceutical closed at 322 yuan, up 38%, with a turnover rate of 81%, a trading volume of 38,200 lots, and a turnover of 121 million yu.
In terms of capital flow data, on July 18, the net inflow of main funds was 13811 million yuan, the net outflow of hot funds was 4961 million yuan, and the net outflow of retail funds was 1885 million yu.
According to the data, Nanxin Pharmaceutical is a high-tech pharmaceutical company specializing in the research and development, production and sales of antiviral and infectious disease prevention and treatment drugs such as influenza, as well as drugs for the treatment of malignant tumors, diabetes and other major diseas.
The 2021 annual performance report shows that the company achieved an operating income of 685 million yuan, a year-on-year decrease of 308%; realized a net profit attributable to shareholders of the listed company of -167 million yuan, a year-on-year stop profit and turned a loss; the basic earnings per share lost 19 yu.
*ST Hengkang: up 303% In addition, *ST Hengkang also rose by more than 30%, reaching 30
As of the close on July 18, 2022, the stock closed at 35 yuan, up 46%, with a turnover rate of 15%, a trading volume of 372,900 lots, and a turnover of 161 million yu.
In terms of capital flow data, on July 18, the net outflow of main funds was 24237 million yuan, the net outflow of hot funds was 1683 million yuan, and the net inflow of retail funds was 2592 million yu.
*ST Hengkang is mainly engaged in medical services and pharmaceutical manufacturi.
The company is based on the "two-wheel drive" big health industry of these two major business.
With medical services as the core, it builds a comprehensive strategic layout for colleges and universities, and its business covers diagnosis, treatment, nursing, Rehabilitation, medical care and other whole industry chains, and at the same time give full play to the discipline advantages of each hospital, build a regional medical center, and form a differentiated competitiveness
In 2021, the company will achieve an operating income of about 016 billion yuan, a year-on-year increase of 49%; the net profit loss attributable to shareholders of the listed company is about 371 million yuan; the basic earnings per share loss is 1991 yu.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
